Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nursing Management of Irritable Bowel Syndrome:Improving Outcomes

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Washington
ClinicalTrials.gov Identifier:
NCT00167635
First received: September 9, 2005
Last updated: May 21, 2009
Last verified: May 2009
  Purpose

The purpose of this study is 1) to determine whether a comprehensive self-management intervention is effective in a sample that includes men and women with irritable bowel syndrome, and 2) to determine whether the comprehensive self-management intervention is as effective when delivered over the telephone as compared to a face-to-face approach.


Condition Intervention Phase
Irritable Bowel Syndrome
Behavioral: cognitive-behavioral
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Nursing Management of Irritable Bowel Syndrome: Improving Outcomes

Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Gastrointestinal symptoms [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Psychological distress [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Cognitive Scale for Functional Bowel Disorders (CFBD) describes 25 cognitive beliefs related to functional bowel disorders. [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Health Related Quality Of Life (HRQOL) will be measures with the Disease Specific Questionnaire-IBS (IBS-DSQ), a 42-item questionnaire. [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sleep disturbance [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Sexual dysfunction [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Catecholamine and cortisol levels (urine) [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Stool frequency/consistency [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]
  • Health care utilization [ Time Frame: baseline, and 3 months, 6 months, 12 months post randomization ] [ Designated as safety issue: No ]

Enrollment: 188
Study Start Date: January 2003
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
Behavioral: cognitive-behavioral
Cognitive-behavioral over 9 weeks
Other Names:
  • Cognitive-behavioral
  • Usual care
Experimental: 2
Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
Behavioral: cognitive-behavioral
Cognitive-behavioral over 9 weeks
Other Names:
  • Cognitive-behavioral
  • Usual care
No Intervention: 3
Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
Behavioral: cognitive-behavioral
Cognitive-behavioral over 9 weeks
Other Names:
  • Cognitive-behavioral
  • Usual care

Detailed Description:

Randomization and Intervention Phase. Upon completing the baseline assessment phase, participants will be randomized to one of 3 treatment groups. A customized computer program will be used to do the randomization in an adaptive manner that ensures the 3 groups remain fairly balanced with respect to possible important predictors of outcomes: age, sex, predominant stool pattern (alternating, constipation-predominant or diarrhea-predominant), and severity of IBS symptoms and psychological symptoms at baseline. When each new participant is randomized, the program will adjust the probabilities of assignment to the three groups so that there is a higher probability of assignment to the group that results in the best balance.

Intervention Groups. Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.

Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-TEL group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.

Usual Care Control Group (UC). Following randomization the participants in the control group will no receive any contacts during the comparable 9-week intervention in the treatment groups.

Follow-up Phase. Participants in all 3 groups will be reassessed at 3-mo, 6-mo, and 12-mo post randomization. At this time the participants will complete questionnaires, a 4 week diary and collect 4 urines.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Irritable Bowel Syndrome

Exclusion Criteria:

  • GI pathology (organic disease)
  • Co-morbid pain disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167635

Locations
United States, Washington
Northgate Executive 1
Seattle, Washington, United States, 98125
University of Washington
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
Investigators
Principal Investigator: Margaret M Heitkemper University of Washington
  More Information

Publications:
Responsible Party: Margaret Heitkember, University of Washington
ClinicalTrials.gov Identifier: NCT00167635     History of Changes
Other Study ID Numbers: 12707-C, 2R01NR04142-5, 97-3895-C 11
Study First Received: September 9, 2005
Last Updated: May 21, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Washington:
Irritable Bowel Syndrome
Cognitive-behavioral intervention
Psychological distress
Quality of life

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Syndrome
Colonic Diseases
Colonic Diseases, Functional
Digestive System Diseases
Disease
Gastrointestinal Diseases
Intestinal Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on November 23, 2014